Astellas Pharma US Inc., which manufactures and sells pharmaceutical drugs, agreed to pay $7.3 million to the federal government to resolve claims it violated the False Claims Act. The drugmaker was charged with marketing and promoting the drug Mycamine for pediatric use, for which it did not have U.S. Food and Drug Administration (FDA) approval. The drug was therefore not eligible for reimbursement through federal health care programs. The federal government will receive $4.2 million of the settlement, and state Medicaid programs will receive $3.1 million. Mycamine is used to treat fungal infections of the esophagus in adults. The FDA ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.